| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 34.9 | 34.6 | 31.8 |
| Other income | 0.2 | 0.2 | 0.2 |
| Total income | 35.1 | 34.8 | 32.0 |
| Profit before exceptional items & tax | 0.5 | -0.9 | 2.7 |
| Profit before tax | 0.5 | -0.9 | 2.7 |
| Net profit | 0.7 | -0.9 | 2.0 |
| Operating margin | 1.4% | -2.6% | 8.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -65.00% |
|---|---|
| Revenue, year on year | +9.70% |
NSE results filing, NSE: ONYX. Figures extracted from the filing.
Onyx Biotec Ltd: key numbers
- Share price
- ₹36.00
- Market cap
- ₹65.28 Cr
- Revenue (annual)
- ₹69.47 Cr
- Net profit (annual)
- ₹-0.21 Cr
- P/E (TTM)
- -304.5×Sector 50.4×
- Promoter holding
- 65.10%
- FII holding
- 1.07%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Onyx Biotec Ltd
All →Onyx Biotec Annual General Meeting
Onyx Biotec Limited will hold its 21st Annual General Meeting on September 28, 2026, via video conferencing to transact the company's business.
Onyx Biotec Management Change
Onyx Biotec Limited has announced a change in the designation of Mr. Naresh Kumar from Whole-Time Director to Executive Director, effective September 3, 2026.
Onyx Biotec Board Meeting Outcome
Onyx Biotec Ltd. announced its board meeting outcomes, including the 21st AGM convening, cost auditor appointment, and a director's designation change to Managing Director.